These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 27625688)

  • 1. Effects of erythropoiesis-stimulating agents on heart failure patients with anemia: a meta-analysis.
    Zhang H; Zhang P; Zhang Y; Yan J; Dong P; Wang Y; Niu X
    Postepy Kardiol Interwencyjnej; 2016; 12(3):247-53. PubMed ID: 27625688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erythropoiesis stimulating agents in heart failure patients with anemia: a meta-analysis.
    Tehrani F; Dhesi P; Daneshvar D; Phan A; Rafique A; Siegel RJ; Cercek B
    Cardiovasc Drugs Ther; 2009 Dec; 23(6):511-8. PubMed ID: 19862609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erythropoiesis-stimulating agents for anaemia in chronic heart failure patients.
    Ngo K; Kotecha D; Walters JA; Manzano L; Palazzuoli A; van Veldhuisen DJ; Flather M
    Cochrane Database Syst Rev; 2010 Jan; (1):CD007613. PubMed ID: 20091643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erythropoietin as a treatment of anemia in heart failure: systematic review of randomized trials.
    Kotecha D; Ngo K; Walters JA; Manzano L; Palazzuoli A; Flather MD
    Am Heart J; 2011 May; 161(5):822-831.e2. PubMed ID: 21570510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, placebo-controlled trial of pentoxifylline on erythropoiesis-stimulating agent hyporesponsiveness in anemic patients with CKD: the Handling Erythropoietin Resistance With Oxpentifylline (HERO) trial.
    Johnson DW; Pascoe EM; Badve SV; Dalziel K; Cass A; Clarke P; Ferrari P; McDonald SP; Morrish AT; Pedagogos E; Perkovic V; Reidlinger D; Scaria A; Walker R; Vergara LA; Hawley CM;
    Am J Kidney Dis; 2015 Jan; 65(1):49-57. PubMed ID: 25115616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of erythropoiesis stimulating therapy for anemia in chronic heart failure: A meta-analysis of randomized clinical trials.
    Kang J; Park J; Lee JM; Park JJ; Choi DJ
    Int J Cardiol; 2016 Sep; 218():12-22. PubMed ID: 27209352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular effects of hemoglobin response in patients receiving epoetin alfa and oral iron in heart failure with a preserved ejection fraction.
    Vullaganti S; Goldsmith J; Teruya S; Alvarez J; Helmke S; Maurer MS
    J Geriatr Cardiol; 2014 Jun; 11(2):100-5. PubMed ID: 25009558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia.
    Ghali JK; Anand IS; Abraham WT; Fonarow GC; Greenberg B; Krum H; Massie BM; Wasserman SM; Trotman ML; Sun Y; Knusel B; Armstrong P;
    Circulation; 2008 Jan; 117(4):526-35. PubMed ID: 18195176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of anemia and iron deficiency in heart failure.
    O'Meara E; de Denus S
    Curr Treat Options Cardiovasc Med; 2010 Dec; 12(6):532-48. PubMed ID: 21063931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aldosterone receptor antagonists decrease mortality and cardiovascular hospitalizations in chronic heart failure with reduced left ventricular ejection fraction, but not in chronic heart failure with preserved left ventricular ejection fraction: a meta-analysis of randomized controlled trials.
    DE Vecchis R; Ariano C
    Minerva Cardioangiol; 2017 Aug; 65(4):427-442. PubMed ID: 27958695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: study-level and patient-level meta-analyses.
    Vansteenkiste J; Glaspy J; Henry D; Ludwig H; Pirker R; Tomita D; Collins H; Crawford J
    Lung Cancer; 2012 Jun; 76(3):478-85. PubMed ID: 22277104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia.
    Palazzuoli A; Silverberg D; Iovine F; Capobianco S; Giannotti G; Calabrò A; Campagna SM; Nuti R
    Am Heart J; 2006 Dec; 152(6):1096.e9-15. PubMed ID: 17161060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective roles of erythropoiesis-stimulating proteins in chronic heart failure with anemia.
    Zhou S; Zhuang Y; Zhao W; Jiang B; Pan H; Zhang X; Peng H; Chen Y
    Exp Ther Med; 2014 Sep; 8(3):863-870. PubMed ID: 25120615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Diagnosis and treatment of anemia in heart failure patients].
    Santilli G; Tarantini L; Baio P; Senni M
    G Ital Cardiol (Rome); 2011 May; 12(5):319-26. PubMed ID: 21593950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of erythropoietin stimulating agents in anemic patients with heart failure: solved and unresolved questions.
    Palazzuoli A; Ruocco G; Pellegrini M; De Gori C; Del Castillo G; Giordano N; Nuti R
    Ther Clin Risk Manag; 2014; 10():641-50. PubMed ID: 25143739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of darbepoetin alpha on right and left ventricular systolic and diastolic function in anemic patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.
    Parissis JT; Kourea K; Panou F; Farmakis D; Paraskevaidis I; Ikonomidis I; Filippatos G; Kremastinos DT
    Am Heart J; 2008 Apr; 155(4):751.e1-7. PubMed ID: 18371487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and economic outcomes in Medicare beneficiaries with stage 3 or stage 4 chronic kidney disease and anemia: the role of intravenous iron therapy.
    Knight TG; Ryan K; Schaefer CP; D'Sylva L; Durden ED
    J Manag Care Pharm; 2010 Oct; 16(8):605-15. PubMed ID: 20866165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency.
    Toblli JE; Lombraña A; Duarte P; Di Gennaro F
    J Am Coll Cardiol; 2007 Oct; 50(17):1657-65. PubMed ID: 17950147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Erythropoietin-Stimulating Agent Responsiveness with Mortality in Hemodialysis and Peritoneal Dialysis Patients.
    Bae MN; Kim SH; Kim YO; Jin DC; Song HC; Choi EJ; Kim YL; Kim YS; Kang SW; Kim NH; Yang CW; Kim YK
    PLoS One; 2015; 10(11):e0143348. PubMed ID: 26588085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of erythropoiesis-stimulating agents among chemotherapy patients with hemoglobin exceeding 12 grams per deciliter.
    Nordstrom BL; Luo W; Fraeman K; Whyte JL; Nordyke RJ
    J Manag Care Pharm; 2008; 14(9):858-69. PubMed ID: 19006442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.